From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer

Amanda L. Tauber, Stephanie S. Schweiker, Stephan M. Levonis*

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

As the most abundant bioactive polyphenol in green tea, epigallocatechin gallate (EGCG) is a promising natural product that should be used in the discovery and development of potential drug leads. Due to its association with chemoprevention, EGCG may find a role in the development of therapeutics for prostate cancer. Natural products have long been used as a scaffold for drug design, as their already noted bioactivity can help accelerate the development of novel treatments. Green tea and the EGCG contained within have become associated with chemoprevention, and both in vitro and in vivo studies have correlated EGCG to inhibiting cell growth and increasing the metabolic stress of cancer cells, possibly giving merit to its long utilized therapeutic use in traditional therapies. There is accumulating evidence to suggest EGCG's role as an inhibitor of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling cascade, acting upon major axis points within cancer survival pathways. The purpose of this review is to examine the research conducted on tea along with EGCG in the areas of the treatment of and/or prevention of cancer. This review discusses Camellia sinensis as well as the bioactive phytochemical compounds contained within. Clinical uses of tea are explored, and possible pathways for activity are discussed before examining the evidence for EGCG's potential for acting on these processes. EGCG is identified as being a possible lead phytochemical for future drug design investigations.

Original languageEnglish
Pages (from-to)23-36
Number of pages14
JournalNutrition Research
Volume74
Early online date10 Dec 2019
DOIs
Publication statusPublished - 1 Feb 2020

Fingerprint

epigallocatechin
Tea
tea
neoplasms
Neoplasms
chemoprevention
Drug Design
Chemoprevention
Phytochemicals
green tea
Biological Products
drugs
therapeutics
phytopharmaceuticals
Therapeutics
Phosphatidylinositol 3-Kinase
Camellia sinensis
Pharmaceutical Preparations
Proto-Oncogene Proteins c-akt
Physiological Stress

Cite this

@article{4af3939c11704e618bb10a07936bafe9,
title = "From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer",
abstract = "As the most abundant bioactive polyphenol in green tea, epigallocatechin gallate (EGCG) is a promising natural product that should be used in the discovery and development of potential drug leads. Due to its association with chemoprevention, EGCG may find a role in the development of therapeutics for prostate cancer. Natural products have long been used as a scaffold for drug design, as their already noted bioactivity can help accelerate the development of novel treatments. Green tea and the EGCG contained within have become associated with chemoprevention, and both in vitro and in vivo studies have correlated EGCG to inhibiting cell growth and increasing the metabolic stress of cancer cells, possibly giving merit to its long utilized therapeutic use in traditional therapies. There is accumulating evidence to suggest EGCG's role as an inhibitor of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling cascade, acting upon major axis points within cancer survival pathways. The purpose of this review is to examine the research conducted on tea along with EGCG in the areas of the treatment of and/or prevention of cancer. This review discusses Camellia sinensis as well as the bioactive phytochemical compounds contained within. Clinical uses of tea are explored, and possible pathways for activity are discussed before examining the evidence for EGCG's potential for acting on these processes. EGCG is identified as being a possible lead phytochemical for future drug design investigations.",
author = "Tauber, {Amanda L.} and Schweiker, {Stephanie S.} and Levonis, {Stephan M.}",
year = "2020",
month = "2",
day = "1",
doi = "10.1016/j.nutres.2019.12.004",
language = "English",
volume = "74",
pages = "23--36",
journal = "Progress in Food and Nutrition Science",
issn = "0271-5317",
publisher = "Elsevier",

}

TY - JOUR

T1 - From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer

AU - Tauber, Amanda L.

AU - Schweiker, Stephanie S.

AU - Levonis, Stephan M.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - As the most abundant bioactive polyphenol in green tea, epigallocatechin gallate (EGCG) is a promising natural product that should be used in the discovery and development of potential drug leads. Due to its association with chemoprevention, EGCG may find a role in the development of therapeutics for prostate cancer. Natural products have long been used as a scaffold for drug design, as their already noted bioactivity can help accelerate the development of novel treatments. Green tea and the EGCG contained within have become associated with chemoprevention, and both in vitro and in vivo studies have correlated EGCG to inhibiting cell growth and increasing the metabolic stress of cancer cells, possibly giving merit to its long utilized therapeutic use in traditional therapies. There is accumulating evidence to suggest EGCG's role as an inhibitor of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling cascade, acting upon major axis points within cancer survival pathways. The purpose of this review is to examine the research conducted on tea along with EGCG in the areas of the treatment of and/or prevention of cancer. This review discusses Camellia sinensis as well as the bioactive phytochemical compounds contained within. Clinical uses of tea are explored, and possible pathways for activity are discussed before examining the evidence for EGCG's potential for acting on these processes. EGCG is identified as being a possible lead phytochemical for future drug design investigations.

AB - As the most abundant bioactive polyphenol in green tea, epigallocatechin gallate (EGCG) is a promising natural product that should be used in the discovery and development of potential drug leads. Due to its association with chemoprevention, EGCG may find a role in the development of therapeutics for prostate cancer. Natural products have long been used as a scaffold for drug design, as their already noted bioactivity can help accelerate the development of novel treatments. Green tea and the EGCG contained within have become associated with chemoprevention, and both in vitro and in vivo studies have correlated EGCG to inhibiting cell growth and increasing the metabolic stress of cancer cells, possibly giving merit to its long utilized therapeutic use in traditional therapies. There is accumulating evidence to suggest EGCG's role as an inhibitor of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling cascade, acting upon major axis points within cancer survival pathways. The purpose of this review is to examine the research conducted on tea along with EGCG in the areas of the treatment of and/or prevention of cancer. This review discusses Camellia sinensis as well as the bioactive phytochemical compounds contained within. Clinical uses of tea are explored, and possible pathways for activity are discussed before examining the evidence for EGCG's potential for acting on these processes. EGCG is identified as being a possible lead phytochemical for future drug design investigations.

UR - http://www.scopus.com/inward/record.url?scp=85077462326&partnerID=8YFLogxK

U2 - 10.1016/j.nutres.2019.12.004

DO - 10.1016/j.nutres.2019.12.004

M3 - Review article

VL - 74

SP - 23

EP - 36

JO - Progress in Food and Nutrition Science

JF - Progress in Food and Nutrition Science

SN - 0271-5317

ER -